CN106163528A - 用于治疗肝脑病的甾族化合物 - Google Patents

用于治疗肝脑病的甾族化合物 Download PDF

Info

Publication number
CN106163528A
CN106163528A CN201580006600.1A CN201580006600A CN106163528A CN 106163528 A CN106163528 A CN 106163528A CN 201580006600 A CN201580006600 A CN 201580006600A CN 106163528 A CN106163528 A CN 106163528A
Authority
CN
China
Prior art keywords
compound
rats
ethynyl
liver
encephalopathy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580006600.1A
Other languages
English (en)
Chinese (zh)
Inventor
M·多弗斯科格
H·默勒
V·费利波
T·贝克斯特伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Umecrine Cognition AB
Original Assignee
Umecrine Cognition AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umecrine Cognition AB filed Critical Umecrine Cognition AB
Priority to CN202110480203.5A priority Critical patent/CN113185566A/zh
Publication of CN106163528A publication Critical patent/CN106163528A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201580006600.1A 2014-01-29 2015-01-14 用于治疗肝脑病的甾族化合物 Pending CN106163528A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110480203.5A CN113185566A (zh) 2014-01-29 2015-01-14 用于治疗肝脑病的甾族化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1450089 2014-01-29
SE1450089-6 2014-01-29
PCT/GB2015/050060 WO2015114308A1 (en) 2014-01-29 2015-01-14 Steroid compound for use in the treatment of hepatic encephalopathy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110480203.5A Division CN113185566A (zh) 2014-01-29 2015-01-14 用于治疗肝脑病的甾族化合物

Publications (1)

Publication Number Publication Date
CN106163528A true CN106163528A (zh) 2016-11-23

Family

ID=52544513

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580006600.1A Pending CN106163528A (zh) 2014-01-29 2015-01-14 用于治疗肝脑病的甾族化合物
CN202110480203.5A Pending CN113185566A (zh) 2014-01-29 2015-01-14 用于治疗肝脑病的甾族化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110480203.5A Pending CN113185566A (zh) 2014-01-29 2015-01-14 用于治疗肝脑病的甾族化合物

Country Status (25)

Country Link
US (3) US20160339040A1 (cg-RX-API-DMAC7.html)
EP (1) EP3099306B1 (cg-RX-API-DMAC7.html)
JP (1) JP6543633B2 (cg-RX-API-DMAC7.html)
KR (1) KR102324667B1 (cg-RX-API-DMAC7.html)
CN (2) CN106163528A (cg-RX-API-DMAC7.html)
AU (1) AU2015212606B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016017620A2 (cg-RX-API-DMAC7.html)
CA (1) CA2935015C (cg-RX-API-DMAC7.html)
CY (1) CY1121464T1 (cg-RX-API-DMAC7.html)
DK (1) DK3099306T3 (cg-RX-API-DMAC7.html)
ES (1) ES2714563T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20190251T1 (cg-RX-API-DMAC7.html)
HU (1) HUE042242T2 (cg-RX-API-DMAC7.html)
IL (1) IL246496B (cg-RX-API-DMAC7.html)
LT (1) LT3099306T (cg-RX-API-DMAC7.html)
ME (1) ME03351B (cg-RX-API-DMAC7.html)
MX (1) MX2016008851A (cg-RX-API-DMAC7.html)
PL (1) PL3099306T3 (cg-RX-API-DMAC7.html)
PT (1) PT3099306T (cg-RX-API-DMAC7.html)
RS (1) RS58375B1 (cg-RX-API-DMAC7.html)
RU (1) RU2684616C2 (cg-RX-API-DMAC7.html)
SI (1) SI3099306T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900133T1 (cg-RX-API-DMAC7.html)
TR (1) TR201901687T4 (cg-RX-API-DMAC7.html)
WO (1) WO2015114308A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111432805A (zh) * 2017-11-27 2020-07-17 梅克里内科尼蒂翁公司 3α-乙炔基-3β-羟基雄甾烷-17-酮肟的药物制剂

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106163528A (zh) 2014-01-29 2016-11-23 梅克芳识别有限公司 用于治疗肝脑病的甾族化合物
TWI748936B (zh) 2015-01-12 2021-12-11 瑞典商優鎂奎認知Ab公司 新穎化合物
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
WO2019053578A1 (en) 2017-09-12 2019-03-21 Eth Zurich TRANSMEMBRANE PH GRADIENT POLYMERSOMES FOR THE QUANTIFICATION OF AMMONIA IN BODY FLUIDS
EP4079307A1 (en) * 2021-04-20 2022-10-26 Umecrine Cognition AB New medical use
US20230134958A1 (en) * 2021-10-29 2023-05-04 Umecrine Cognition Ab New medical treatment
EP4389129A1 (en) * 2022-12-22 2024-06-26 Umecrine Cognition AB 3a-ethynyl-3beta hydroxyandrostan 17-one oxime for treating parkinson's disease and l-dopa-induced dyskinesia
WO2025252725A1 (en) 2024-06-04 2025-12-11 Umecrine Cognition Ab Novel pharmaceutical formulation of golexanolone
WO2025252724A1 (en) 2024-06-04 2025-12-11 Umecrine Cognition Ab Novel pharmaceutical formulation of golexanolone

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1607954A (zh) * 2001-12-27 2005-04-20 梅克芳股份公司 用于治疗中枢神经系统功能紊乱的孕烷类固醇
WO2007103162A2 (en) * 2006-03-01 2007-09-13 Samaritan Pharmaceuticals, Inc. Structure based drug design of steroidogenesis inhibitors
US20080119416A1 (en) * 2006-11-21 2008-05-22 Umecrine Ab New steroids having increased water solubility and resistance against metabolism, and methods for their production
CN101784558A (zh) * 2007-06-20 2010-07-21 生态自然E.A.有限公司 神经甾体化合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2713061A (en) 1951-04-06 1955-07-12 Schering Ag 3-methyl androstanes
FR1463755A (fr) 1960-01-26 1966-07-22 Nouveaux stéroïdes de la série de l'androstane et leur procédé de préparation
US3173932A (en) 1962-11-02 1965-03-16 American Cyanamid Co 15-substituted estra-1, 3, 5(10)-trienes
FR2685332A1 (fr) 1991-12-20 1993-06-25 Roussel Uclaf Nouveaux 19-nor sterouides ayant en position 11beta une chaine thiocarbonee, leur procede de preparation et les intermediaires et leur application a titre de medicaments.
JP4008024B2 (ja) 1993-05-24 2007-11-14 パーデュー、ファーマ、リミテッド、パートナーシップ Gabaaレセプター複合体と相互作用させるための化合物
CN1270718C (zh) 1998-03-11 2006-08-23 托布乔恩·贝克斯托罗姆 表别孕烷醇酮在制备治疗甾族化合物诱导的疾病的药物中的应用
US6593321B2 (en) 2001-06-11 2003-07-15 Southwest Foundation For Biomedical Research 2-alkoxyestradiol analogs with antiproliferative and antimitotic activity
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
PT2319581E (pt) 2004-11-26 2015-06-30 Ucl Business Plc Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
BRPI0920465A2 (pt) * 2008-10-02 2018-03-20 Salix Pharmaceuticals, Inc. metodo de tratamento de encefalopatia hepática
ES2517340T3 (es) 2009-06-08 2014-11-03 Ucl Business Plc Tratamiento de la hipertensión portal usando L-ornitina y fenilacetato
EP3019074B1 (en) 2013-09-30 2018-08-29 Horizon Therapeutics, LLC Diagnosing, grading, monitoring, and treating hepatic encephalopathy
CN106163528A (zh) 2014-01-29 2016-11-23 梅克芳识别有限公司 用于治疗肝脑病的甾族化合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1607954A (zh) * 2001-12-27 2005-04-20 梅克芳股份公司 用于治疗中枢神经系统功能紊乱的孕烷类固醇
WO2007103162A2 (en) * 2006-03-01 2007-09-13 Samaritan Pharmaceuticals, Inc. Structure based drug design of steroidogenesis inhibitors
US20080119416A1 (en) * 2006-11-21 2008-05-22 Umecrine Ab New steroids having increased water solubility and resistance against metabolism, and methods for their production
WO2008063128A1 (en) * 2006-11-21 2008-05-29 Umecrine Ab The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders
CN101784558A (zh) * 2007-06-20 2010-07-21 生态自然E.A.有限公司 神经甾体化合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MARK L.BASSETT ET AL: "Amelioration of hepatic encephalophathy by pharmacologic antagonism of the gabaa-benzodiazapine receptor complex in a rabbit model of fulminant hepatic failure", 《GASTROENTEROLOGY》 *
RAVI PRAKASH ET AL: "Mechanisms, diagnosis and management of hepatic encephalopathy", 《GASTROENTEROLOGY & HEPATOLOGY》 *
曹霞等: "《病理生理学》", 28 February 2013, 武汉:华中科技大学出版社 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111432805A (zh) * 2017-11-27 2020-07-17 梅克里内科尼蒂翁公司 3α-乙炔基-3β-羟基雄甾烷-17-酮肟的药物制剂

Also Published As

Publication number Publication date
WO2015114308A1 (en) 2015-08-06
IL246496A0 (en) 2016-08-31
MX2016008851A (es) 2017-03-23
US10342804B2 (en) 2019-07-09
US9801894B2 (en) 2017-10-31
CN113185566A (zh) 2021-07-30
PT3099306T (pt) 2019-03-21
EP3099306B1 (en) 2018-12-12
IL246496B (en) 2019-09-26
CA2935015C (en) 2022-05-31
CA2935015A1 (en) 2015-08-06
RU2684616C2 (ru) 2019-04-10
NZ721622A (en) 2020-11-27
KR20160105922A (ko) 2016-09-07
AU2015212606B2 (en) 2019-11-21
JP6543633B2 (ja) 2019-07-10
US20180015103A1 (en) 2018-01-18
CY1121464T1 (el) 2020-05-29
RS58375B1 (sr) 2019-03-29
SMT201900133T1 (it) 2019-05-10
BR112016017620A2 (pt) 2017-08-08
JP2017507113A (ja) 2017-03-16
WO2015114308A8 (en) 2016-07-21
TR201901687T4 (tr) 2019-02-21
SI3099306T1 (sl) 2019-03-29
AU2015212606A1 (en) 2016-07-14
KR102324667B1 (ko) 2021-11-10
LT3099306T (lt) 2019-03-12
RU2016127558A (ru) 2018-03-05
ME03351B (me) 2019-10-20
RU2016127558A3 (cg-RX-API-DMAC7.html) 2018-09-27
HRP20190251T1 (hr) 2019-04-05
ES2714563T3 (es) 2019-05-29
US20160339040A1 (en) 2016-11-24
DK3099306T3 (en) 2019-03-18
PL3099306T3 (pl) 2019-06-28
HUE042242T2 (hu) 2019-06-28
EP3099306A1 (en) 2016-12-07
US20170056416A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
US10342804B2 (en) Steroid compound for use in the treatment of hepatic encephalopathy
JP2017507113A5 (cg-RX-API-DMAC7.html)
JP7033642B2 (ja) 選択的s1p1レセプターアゴニストを含む薬学的合剤
JP6876047B2 (ja) ミトコンドリアの活性酸素種(ros)産生に関連する疾患の治療のための化合物
TW202207928A (zh) 肝病之組合治療
TW202207927A (zh) 肝病之組合治療
TW202327589A (zh) 肝病之組合療法
JP2025522788A (ja) アミノステロール化合物、アミノステロール-シクロデキストリン製剤及びその使用方法
BR112021001322A2 (pt) 17 beta-heterociclil-digitalis como compostos para o tratamento de insuficiência cardíaca
US20210308138A1 (en) Tissue transglutaminase modulators for medicinal use
NZ721622B2 (en) Steroid compound for use in the treatment of hepatic encephalopathy
HK1228753A1 (en) Steroid compound for use in the treatment of hepatic encephalopathy
HK1228753B (en) Steroid compound for use in the treatment of hepatic encephalopathy
WO2015197562A1 (en) Methods and pharmaceutical compositions for the treatment of disorders or diseases associated with ryanodine receptor dysfunction
WO2026003229A1 (fr) Derives de fluoroethylnormemantine pour leur utilisation en tant que medicament
BR112018073679B1 (pt) Compostos derivados halo-substituídos do sobetirome com características farmacológicas aprimoradas

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20161123

RJ01 Rejection of invention patent application after publication